Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinoma

被引:5
|
作者
Korkmaz, Mustafa [1 ]
Erylmaz, Melek Karakurt [1 ]
机构
[1] Necmettin Erbakan Univ, Meram Med Fac, Dept Med Oncol, Konya, Turkiye
关键词
Sunitinib; Pazopanib; Renal cell carcinoma; Prognostic marker; Overall survival; Inflammatory; PROGNOSTIC VALUE; SUNITINIB; PAZOPANIB; CANCER; INDEX;
D O I
10.29271/jcpsp.2023.06.653
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To identify prognostic inflammatory markers in metastatic renal cell carcinoma (mRCC) patients who received anti-vascular endothelial growth factor receptor (VEGFR) agents. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey, between January 2015 and December 2021. Methodology: A total of 110 patients with mRCC who received sunitinib or pazopanib for at least 3 months were enrolled. Hemogram, C-reactive protein (CRP) and albumin values of the patients, CRP to albumin ratio (CAR), neutrophil-lymphocyte ratio (NLR), platelet -lym-phocyte ratio (PLR), systemic immune-inflammation index (SII), prognostic nutrition index (PNI) and systemic inflammatory response indexes (SIRI) were calculated and recorded. Progression-free survival and overall survival analyses of the patients were performed using the Kaplan-Meier method. Cox regression method was used to identify prognostic factors. Variables found to be significant in univariate analysis were enrolled in multivariate analysis. Results: In the univariate analysis for median overall survival (mOS), whether or not surgery was applied as the primary treatment option, grade, lymphovascular invasion (LVI), International Metastatic RCC Database Consortium (IMDC) score, CAR, NLR, PLR, SII, PNI and SIRI were found to be statistically significant. Systemic inflammation markers (CAR, NLR, PLR, PNI, SII and SIRI) were found to be independent prognostic markers for mOS as a result of Cox multivariate analysis. Conclusion: CAR, NLR, PLR, SII, PNI, and SIRI values measured before anti-VEGFR treatment in patients with mRCC may be of addi-tional prognostic significance. These markers, which are calculated by using parameters that are always measured in routine practice, such as complete blood count (CBC), albumin, and CRP levels, are easy and inexpensive methods that give an idea about the course of the disease.
引用
收藏
页码:653 / 658
页数:6
相关论文
共 50 条
  • [1] Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma
    Miyake, H.
    Momozono, H.
    Fujisawa, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S513 - S513
  • [2] Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
    Yaman, Samet
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Akinci, Muhammed Bulent
    Yalcin, Bulent
    FUTURE ONCOLOGY, 2019, 15 (09) : 925 - 927
  • [3] Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
    Wang, Zhaojuan
    Qin, Yujie
    Chai, Xuxia
    Lu, Lina
    Xue, Ping
    Lu, Runrun
    Miao, Chengrui
    Ma, Haimei
    Hu, Xiaoyi
    Yao, Jiaxi
    CANCER CONTROL, 2023, 30
  • [4] Optimal sequential therapy using tyrosine kinase inhibitors as the first-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study
    Jo, Jung Ki
    Kang, Minyong
    Chung, Jinsoo
    Kwak, Cheol
    Hong, Sung-Hoo
    Song, Cheryn
    Park, Jae Young
    Jeong, Chang Wook
    Choi, Seok Hwan
    Kim, Sung Han
    Hwang, Eu Chang
    Lee, Chan Ho
    Lee, Hakmin
    ASIAN JOURNAL OF UROLOGY, 2024, 11 (03) : 450 - 459
  • [5] EARLY TUMOR SHRINKAGE UNDER FIRST-LINE TYROSINE KINASE INHIBITOR AS A SURROGATE ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Miyake, Hideaki
    Harada, Ken-ichi
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2015, 193 (04): : E759 - E760
  • [6] Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?
    Mickisch, G.
    Peters, I.
    Gruellich, C.
    Mudra, T.
    Doehn, C.
    UROLOGE, 2020, 59 (12): : 1504 - 1511
  • [7] Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
    Roviello, Giandomenico
    Buti, Sebastiano
    Cattrini, Carlo
    Mennitto, Alessia
    Messina, Carlo
    Airoldi, Chiara
    Vannini, Gianmarco
    Bersanelli, Melissa
    THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
  • [8] Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
    Poprach, Alexandr
    Rumanova, Kristina
    Lakomy, Radek
    Chloupkova, Renata
    Stanik, Michal
    Pokrivcak, Tomas
    Kiss, Igor
    Slaby, Ondrej
    Studentova, Hana
    Melichar, Bohuslav
    Juracek, Jaroslav
    Fiala, Ondrej
    Kopecky, Jindrich
    Kopeckova, Katerina
    Zemanova, Milada
    Buchler, Tomas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (04) : 294.e1 - 294.e8
  • [9] First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience
    Rudresha, A. H.
    Chaudhuri, Tamojit
    Lakshmaiah, K. C.
    Babu, Govind K.
    Lokanatha, D.
    Jacob, Linu Abraham
    Babu, Suresh M. C.
    Lokesh, K. N.
    Rajeev, L. K.
    INDIAN JOURNAL OF CANCER, 2017, 54 (04) : 626 - 630
  • [10] Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.
    Hess, G. P.
    Chen, C.
    Liu, Z.
    Gesme, D. H.
    Agarwala, S. S.
    Hill, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)